# US 2024/0197642 A1 · Novel drug delivery composition and process for blood-brain barrier crossing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197642 A1
- Document ID: US20240197642A1
- Status: Published application
- Kind: A1
- Application number: 18/238,973
- Filed: 2023-08-28
- Published: 2024-06-20
- Earliest claimed: 2020-11-17
- Assignees: Cytodigm, Inc.
- Applicants: Cytodigm, Inc.
- Inventors: Bin Wu; Nicholas J. Boylan; Zimeng Wang; Jienu Xu
- Web page: https://patentgrep.com/patent/US20240197642A1

## CPC

- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

This invention provides polymeric nanoparticles presenting non-conjugated BBB-crossing ligands on their surfaces, compositions and methods of use thereof, as well as non-conjugation methods to produce nanoparticles having BBB-crossing agents on their surfaces.

## Claims

### Claim 1

A method of delivering an active agent to a central nervous system in a mammal comprising administering particles encapsulating the active agent comprising a biodegradable polymer and a surfactant intertwined on the surface thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the particles are microparticles or nanoparticles.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biodegradable polymer is polylactide (PLA), poly(lactide-co-glycolide) (PLGA), copolymers of ethylene glycol and lactide/glycolide (PEG-PLGA), copolymers of ethylene glycol and lactide (PEG-PLA), copolymers of ethylene glycol and glycolide (PEG-PGA), poly(ethylene glycol) (PEG), polycaprolactone (PCL), polyanhydrides (PANH), poly(ortho esters), polycyanoacrylates, poly(hydroxyalkanoate)s (PHAs), poly(sebasic acid), polyphosphazenes, polyphosphoesters, modified poly(saccharide)s, poly(amino esters), dendrimers, chitosan, gelatin, human serum albumin (HSA), hyluronic acid, dextran, mixtures and copolymers thereof, preferably PLGA or poly(n-butyl cyanoacrylate) (PBCA).

### Claim 4 (depends on 1)

The method of claim 1, wherein the biodegradable polymer is PLGA or PBCA.

### Claim 5 (depends on 4)

The method of claim 4, wherein the surfactant and biodegradable polymer form an interpenetrating network.

### Claim 6 (depends on 4)

The method of claim 4, wherein the surfactant is a polymer.

### Claim 7 (depends on 6)

The method of claim 6, wherein the surfactant is a polysorbate.

### Claim 8 (depends on 6)

The method of claim 6, wherein the surfactant is polysorbate 80.

### Claim 9 (depends on 6)

The method of claim 6, wherein the surfactant is a poloxamer.

### Claim 10 (depends on 6)

The method of claim 6, where in the surfactant is poloxamer 188.

### Claim 11 (depends on 1)

The method of claim 1, wherein the active agent is a selected from the group containing small molecule compound, peptide, protein, oligonucleotide, RNA and DNA.

### Claim 12 (depends on 10)

The method of claim 10, wherein the active agent is an oligonucleotide.

### Claim 13 (depends on 11)

The method of claim 11, where in the active agent is an antisense oligonucleotide.

### Claim 14 (depends on 1)

The method of claim 1, further comprising a targeting agent bound to the surface of the particles.
